Evaluation of the VEGF pathway according to colon location has shown that it is more active in the left colon than in the right colon.[9,10] Although it has been suggested that regorafenib, which primarily shows its effect via the VEGF receptor, may have different efficacies in right- and left-sided colon cancers, our study demonstrated no effect of colon cancer location on treatment response. Here, VEGFA is linked to malignant colon neoplasm.